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Although kidney transplantation remains the best treatment for end-stage renal failure, it is 
limited by chronic humoral aggression of the graft vasculature by donor-specific antibodies 
(DSAs). The complement-independent mechanisms that lead to the antibody-mediated 
rejection (ABMR) of kidney allografts remain poorly understood. Increasing lines of evi-
dence have revealed the relevance of natural killer (NK) cells as innate immune effectors 
of antibody-dependent cellular cytotoxicity (ADCC), but few studies have investigated 
their alloreactive potential in the context of solid organ transplantation. Our study aimed 
to investigate the potential contribution of the antibody-dependent alloreactive function 
of NK cells to kidney graft dysfunction. We first conducted an observational study to 
investigate whether the cytotoxic function of NK cells is associated with chronic allograft 
dysfunction. The NK-Cellular Humoral Activation Test (NK-CHAT) was designed to eval-
uate the recipient and antibody-dependent reactivity of NK cells against allogeneic target 
cells. The release of CD107a/Lamp1+ cytotoxic granules, resulting from the recognition 
of rituximab-coated B cells by NK cells, was analyzed in 148 kidney transplant recipients 
(KTRs, mean graft duration: 6.2 years). Enhanced ADCC responsiveness was associ-
ated with reduced graft function and identified as an independent risk factor predicting 
a decline in the estimated glomerular filtration rate over a 1-year period (hazard ratio: 
2.83). In a second approach, we used the NK-CHAT to reveal the cytotoxic potential 
of circulating alloantibodies in vitro. The level of CD16 engagement resulting from the 
in vitro recognition of serum-coated allogeneic B cells or splenic cells was further identi-
fied as a specific marker of DSA-induced ADCC. The NK-CHAT scoring of sera obtained 
2Legris et al. DSA-Induced NK Cell Alloreactivity
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 288
from 40 patients at the time of transplant biopsy was associated with ABMR diagnosis. 
Our findings indicate that despite the administration of immunosuppressive treatments, 
robust ADCC responsiveness can be maintained in some KTRs. Because it evaluates 
both the Fab recognition of alloantigens and Fc-driven NK cell activation, the NK-CHAT 
represents a potentially valuable tool for the non-invasive and individualized evaluation of 
humoral risk during transplantation.
Keywords: natural killer cells, kidney transplantation, donor-specific antibodies, antibody-dependent cellular 
cytotoxicity, antibody-mediated rejection
inTrODUcTiOn
Kidney transplantation is the best treatment for patients with end-
stage chronic kidney disease (CKD). However, long-term graft 
survival is limited by numerous factors, including inadequate 
control of the immune response to the allograft vasculature (1–3). 
Antibody-mediated rejection (ABMR) is a major cause of long-
term transplant failure (2, 4, 5). De novo donor-specific antibodies 
(dnDSA) have been identified as major contributors to chronic 
ABMR and have been associated with graft microvascular injury 
(6–9) and arterial intimal fibrosis (10, 11). Despite advances in 
the development of the multiplex solid-phase single-antigen 
bead assay (SABA), which detects circulating donor-specific 
antibodies (DSAs) (12, 13) and their capacity to bind C1q or C3d 
(14–18), predicting the graft outcome in sensitized transplant 
recipients remains difficult (16, 19–23). A better understanding 
of the underlying mechanisms that contribute to ABMR is thus 
of key importance for improving therapeutic strategies. Recent 
findings indicate that, in addition to complement-dependent 
mechanisms, antibody-dependent cellular cytotoxicity (ADCC) 
involving γδ T cells or natural killer (NK) cells contributes to 
DSA-mediated graft injury (24–33). The NK cell molecular 
signatures from transplant biopsies of patients with ABMR (32, 
34–37) suggest that NK cell activation is associated with humoral 
allograft vasculopathy (38, 39). Although NK cells are known 
cytotoxic effectors of the innate immune responses to antibodies, 
their potential pathogenic role in transplant rejection remains 
poorly documented. The antitumor efficiency of therapeutic 
monoclonal antibodies has been shown to be dependent on 
the expression of CD16-FcRγIIIA on NK cells (40, 41). FcγR 
polymorphisms have also been suggested as predisposing fac-
tors to infectious complications after liver transplantation (42). 
Similarly, we hypothesized that antibody-dependent cytotoxicity 
may be partly conditioned by the intrinsic capacity of the recipi-
ent NK cells to form conjugates with antibody-coated donor cells. 
In the transplant setting, the recipient NK cell alloreactivity may 
be affected by numerous factors, such as immunosuppressive 
drugs, infection, uremia, and inflammatory stresses (27, 43–48). 
Therefore, we aimed to investigate the potential link between NK 
cell cytotoxicity and allograft function in a cohort of late kidney 
transplant recipients (KTRs). An in vitro NK-Cellular Humoral 
Activation Test (NK-CHAT) was designed to address the fol-
lowing: (1) the potential link between NK cell activation and 
transplant dysfunction and (2) the potential toxicity of dnDSAs 
in promoting NK cell activation.
MaTerials anD MeThODs
Patients and study Design
Study approval was obtained from the Agence Française de 
Sécurité Sanitaire (Afssaps Ref B805-1860) and from the Comité 
de Protection des Personnes SUD Méditerranée I. The study was 
supervised by the Institut National de la Santé et de la Recherche 
Médicale (INSERM, protocol granted in 2008 under Ref ID RCB 
2008-A00604-51, C07-17).
Kidney transplant recipients were prospectively enrolled 
in the study from November 2008 to November 2011 at the 
Centre de Nephrologie et Transplantation Rénale, Hôpital de la 
Conception, Marseille. Patients considered for inclusion under-
went transplantation between 2001 and 2005 (>3  years post 
graft) as part of a follow-up for a previous study (49). Patients 
with insufficient peripheral blood mononuclear cells (PBMCs) 
to perform the functional test or patients lacking follow-up data 
for kidney graft function after 1 year were not considered in the 
analysis (n = 42). The distribution of the variables for this group 
of 42 patients with missing data were not significantly different 
from that found for the cohort of 148 KTRs who were included 
in the final study cohort. The baseline characteristics of the 148 
KTRs are summarized in Table 1. Renal function decline during 
follow-up was defined as either a 10% loss in the estimated glo-
merular filtration rate (eGFR) (mL/min/1.73 m2, defined with the 
MDRD simplified equation, n = 51) or renal graft failure (n = 9). 
The control group was composed of 86 volunteer blood donors 
without renal failure.
cells, Plasma, and sera
Peripheral blood mononuclear cells for use as effector cells were 
obtained from healthy volunteer blood donors and KTR patients 
and were isolated using a Ficoll gradient. The cells used as targets 
in the NK-CHAT assay included the following: cells from the 
K562 cell line, cells from a B-EBV immortalized cell line [human 
leukocyte antigen (HLA)-genotype Table  2], NK cell-depleted 
PBMCs, and the residual donor spleen cells from the pretrans-
plant cross-matching. The splenic or renal tissues were minced 
and homogenized by incubation with 50  μg/mL collagenase 
1A (Sigma C9891) for 30 min at 37°C. Plasmapheresis samples 
(500 mL), containing HLA-A2 or HLA-DR4 DSA, were collected 
during the first round of ABMR desensitization therapy from two 
patients. KTR serum samples were obtained before the initiation 
of ABMR treatment and blindly analyzed for NK-CHAT activity. 
NK-CHAT standardization was achieved using a monoclonal 
TaBle 1 | characteristics of the 148 KTrs according to transplant function.
Variable KTr with egFr < 60 KTr with egFr ≥ 60 p value cTl
KTr with egFr < 60 versus  
KTr with egFr ≥ 60 
recipient n = 148 92 (62%) 56 (38%) 86
Men (%) 55 (60%) 36 (64%) ns 47 (55%)
Age at transplant (year, mean ± SD) 45 ± 13 32 ± 13 0.07 NA
Body mass index (kg/m2) at transplant 23 ± 4** 23 ± 4* ns 25 ± 5
Donor
Men (%) 63 (67.7%) 41 (74.5%) ns N.A
Age (year, mean ± SD) 45 ± 13 32 ± 13 <0.0001 N.A
No of HLA mismatch (min–max) 3 (0–5) 3 (1–4) ns N.A
antecedent/risk factors
Time on dialysis, months 33 (18.5–55.5) 25 (14–52) ns N.A
Second or third transplantation 12 (13%) 6 (11%) ns N.A
Delayed graft function 24 (26%) 8 (14.5%) 0.091t N.A
eGFR at 1 year posttransplant (M12) 45 ± 13 63 ± 11.5 <0.0001 N.A
Acute rejection 8 (8.7%) 1 (1.8%) 0.088 N.A
characteristics at time of inclusion
Time post graft (year, mean ± SD) 6.3 ± 1.8 6.03 ± 1.7 ns N.A
Serum creatinine, μmol/L (mean ± SD) 161 ± 58*** 89 ± 14*** <0.0001 73 ± 14
eGFR (mL/min/1.73 m2, mean ± SD) 41.3 ± 11*** 75.6 ± 13*** <0.0001 96 ± 18
Obesity (BMI > 30) 13 (14.1%) 4 (7.1%) 0.196 N.A
Current smokers 17 (18.5%) 4 (7.1%) 0.055 N.A
Diabetes 18 (19.6%) 8 (14.3%) ns N.A
Hypertension 91 (99%) 51 (91.1%) 0.019 N.A
Cardiovascular history 16 (17.4%) 17 (30.4%) ns N.A
DSA at time of inclusion 13 (14%) 2 (4%) 0.039 N.A
immunosuppressive therapy
Cyclosporine 42 (46%) 21 (37.5%) ns N.A
Mycophenolate mofetil 46 (49.5%) 32 (58.2%) ns N.A
Azathioprine 22 (24%) 16 (29%) ns N.A
Steroids 86 (92.5%) 51 (92.8%) ns N.A
nK cell number and cytotoxic function
% NK cells (median, 25–75 pct) 9.1 (5.6–15) 10.1 (6.5–15) ns 10.4 (9–14.5)
Number of NK cells/mm3 (median, 25–75 pct) 118 (88–180) 149 (93–224) 0.103t 197 (142–264)
nK cell activation toward target (%cD107a/lamp1)
Natural cytotoxicity toward B cells 5.8 (4.3–9.1) 5.4 (3.7–8.6) ns 6.9 (4.3–11)
ADCC: B cells + rituximab 29.4 (18.7–37) 22.6 (15–39) 0.008 31 (25–40)
egFr loss ≥10% 33 (36%) 18 (32%) ns N.A
The p values from the comparison of KTRs and healthy individuals (eGFR ≥ 60, CTL) were used to assess the significance of the differences (*p < 0.05, **p < 0.01, ***p < 0.0001); 
tshows the differences with p values <0.2, and ns indicates the non-significant differences (p > 0.2). The progression of CKD was evaluated as an eGFR decrease of at least 10% 
from the time of inclusion in the study (time of NK cell evaluation) to 1 year later. According to the distribution of variables, the results are shown as numbers and percentages, 
means ± SD, or medians (25–75th percentile ranges).
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therapeutic IgG-recognizing CD20, rituximab (obtained from 
the residual samples that could not be used in the clinics or that 
were beyond the expiration date). The samples were obtained 
under institutional approval provided by the Pharmacy and 
Nephrology Department of Assistance Publique des Hôpitaux 
de Marseille.
The plasma samples obtained during the first round of 
plasmapheresis treatment from two ABMR patients were used 
to validate the performance of the NK-CHAT in detecting anti 
HLA-A2 and HLA-DR4 DSA reactivity. Serum and plasmapher-
esis samples (500 mL) were collected and aliquoted during the 
first round of ABMR desensitization therapy from two KTRs 
completing 10 plasmapheresis sessions, specifically before the 
initiation of other treatments using pulse methylprednisolone, 
intravenous immunoglobulin, and rituximab treatment to ensure 
that rituximab reactivity does not interfere in the experiments 
conducted with these plasma samples. The first patient (patient 1) 
was a 59-year-old man with HLA-A2 dnDSAs who experienced 
an acute C4d-positive ABMR rejection 8 years after his first renal 
transplantation. The second patient (patient 2) was a 29-year-old 
woman with HLA-DR4 dnDSAs who experienced an acute C4d-
positive ABMR rejection episode with cellular borderline changes 
8 years after her first transplantation. Antibodies from serum or 
plasma were purified using Protein A columns and Gentle Ag/A 
binding and elution buffers (Pierce 20356 and 21030). Before 
introduction into the NK-CHAT assay, the purified antibodies 
were dialyzed against PBS buffer (2 × 2 h and overnight) using a 
10-kDa dialysis cassette.
TaBle 2 | Univariate and multivariate analysis of factors associated with the progression to cKD at 1 year post-enrollment into the study.
≥10% egFr loss Univariate analysis estimates: asymptotic cox regression multivariate
Variables in the model p B se p hr 95% ci for exp (B) (lower–upper)
CD107a/Lamp1URI >3 0.033 1.04 0.50 0.038 2.83 1.06 7.57
eGFR 1 year after transplantation 0.001 −0.06 0.02 0.001 0.94 0.91 0.98
eGFR at time of evaluation 0.386 0.03 0.01 0.036 1.03 1.00 1.05
Maintenance treatment: azathioprine 0.044 0.93 0.48 0.052 2.53 0.99 6.47
Smoking of time of enrollment 0.179t −0.05 0.44 0.273 0.62 0.26 1.46
Presence of DSA at time of enrollment 0.214 −0.55 0.65 0.401 0.58 0.16 2.07
Recipient age at transplant ≥55 years 0.157t −0.32 0.39 0.416 0.73 0.34 1.57
Time posttransplant at time of enrollment 0.333 0.05 0.11 0.640 1.05 0.85 1.30
Number of NK cells at time of enrollment 0.192t −0.001 0.002 0.688 1.00 1.00 1.00
Donor age at time of transplant 0.049 0.004 0.01 0.761 1.00 0.98 1.03
The univariate analysis defined variables that were significantly associated (p < 0.05) or tended to associate (tp < 0.2) with deterioration of kidney graft function (≥10% eGFR loss 
1 year post-enrollment). These variables were used to construct a multivariate Cox regression model to analyze the link between NK cell activation corresponding to the intermediate 
and high ADCC responses observed in the KTR cohort (CD107a/Lamp1URI ≥ 2.98) and risk of a further 10% decline in allograft function, evaluated in reference to the eGFR 
values obtained at the time of enrollment and after a median period of 13 months post-enrollment (min–max, 11–41 months post-inclusion). Although found to not be significantly 
associated with the degradation of kidney graft function using univariate analysis, variables such as the eGFR at the time of NK cell evaluation, the time posttransplant, and the 
presence of circulating dnDSAs at the time of inclusion were introduced into the multivariate model to control whether the association between NK activation and CKD progression 
was related to initial graft dysfunction and immunization status.
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identification of Donor-specific  
anti-hla alloantibodies
The detection of HLA-specific antibodies in serum samples was 
performed using standard techniques. The presence of allograft-
specific antibodies was screened through CDC and Luminex 
screening assays (LAScreen® mixed, One Lambda, Canoga Park, 
CA, USA) using Luminex flow beads (LAScan™ 100, Luminex, 
Austin, TX, USA). To determine their antibody specificity, all 
samples with a positive screening result were further evaluated 
using “Single-Antigen” Gen-Probe Lifecodes reagents (Lifecodes 
LSA class I and Lifecodes LSA class II kits, Immucor, Norcross, 
GA, USA) according to the recommendations of the manufacturer 
and current guidelines (16, 50). The DSAs present in the samples 
were analyzed at the time of biopsy and were further characterized 
using single-antigen flow bead assays according to the manufac-
turer’s recommended protocol (LAScreen® Single Antigen class 
I or LAScreen® Single Antigen class II, One Lambda, Canoga 
Park, CA, USA). Median fluorescence intensity (MFI) values 
were obtained using the baseline formula proposed by Fusion 3.2 
software. The percentage of PRAs for the single-antigen assays 
were calculated according to the manufacturer’s instructions as 
the percentage of positive bead reactions among the 99 class I 
beads and 97 class II beads. Cytotoxic cross-match assays were 
performed with donor PBMCs or splenic cells according to the 
protocol recommended by the Eurotransplant Organization using 
a standard microcytotoxicity assay. The CDC showed positive 
results when at least 50% of the cells were dead. Autoreaction was 
detected by incubating the patient’s serum with autologous effec-
tor lymphocytes. IgM reactivity was excluded through prior treat-
ment of the tested sera with dithiothreitol (Fluka BioChemika).
Flow cytometry analysis  
of antibody ligation
Antibody ligation to target cells was analyzed using anti-human 
Fc antibody. The target cells (105) were incubated with 10 μL of 
the FcR-blocking reagent (Miltenyi 130-059-901) and 90 μL for 
serum 0 min at 4°C, washed in PBS, incubated with 20 μL of sera 
or plasma and 80 μL of PBS for 30 min at 4°C, and then washed 
again in PBS. Binding was evaluated by incubating the serum- or 
plasma-coated cells with a secondary goat F(ab′)2 anti-human-Fc 
antibody conjugated to PE for 20 min at 4°C (Beckman Coulter 
IM0550). Acquisition and analysis of the MFI of the gated alloge-
neic target cells were performed using a Beckman Coulter Navios 
Cytometer.
absorption of hla class i antibodies
Platelets were obtained from the blood bank service as units of 
platelet concentrate and were processed as follows. First, the plate-
lets were centrifuged at 200 g for 40 min in 50-mL centrifuge tubes. 
The supernatant was removed, and the platelets were centrifuged 
again at 2,000 g for 15 min. After removal of the supernatant, 20 mL 
of 0.8% ammonium chloride was added to achieve red blood cell 
lysis, and the mixture was placed on a rotary mixer for 50 min. The 
platelets were washed twice with 1% Tris-buffered EDTA/saline 
and stored in a solution containing 0.1% sodium azide until their 
use for antibody absorption. Prior to absorption, the platelets were 
centrifuged at 2,000 g for 20 min, the supernatant was removed, 
and the platelets were washed twice with complement fixing buffer 
(Ovoid). A 50% volume of complement fixing buffer was added to 
packed platelets. Then, 1 mL of the above-described mixture was 
placed in a microcentrifuge tube and centrifuged at 10,000 g for 
5 min, and the supernatant was removed. A volume of 0.25 mL 
of each sera sample was mixed, incubated at 22°C for 2 h, and 
centrifuged at 10,000 g for 5 min, and the absorption procedure 
was repeated with an overnight incubation at 22°C. Non-platelet- 
and platelet-absorbed sera were stored at 4°C until further use.
Phenotypic analysis of  
antibody-Dependent nK cell activation
The NK-CHAT was performed to analyze the antibody-
dependent activation potential of NK effector cells resulting from 
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their exposure to rituximab or DSA-coated target cells. Briefly, 
500,000 target cells (B-EBV cell lines, NK cell-depleted PBMCs, 
or spleen cells) were incubated with control (CTL) unsensitized 
male human AB serum (CTL, Lonza) to block FcRs, rinsed, and 
incubated for 15 min in the presence of 20% KTR serum or CTL 
serum either supplemented or not supplemented with 10 μg/mL 
rituximab or purified IgG. The samples were then rinsed to remove 
any unbound antibodies. Effector cell PBMCs were incubated 
with antibody-coated targets for 3 h at 37°C using a 1:1 effector-
to-target ratio in the presence of Golgi Stop (Becton Dickinson 
554724) and CD107a-PC5 (Becton Dickinson 555802). In several 
experiments, serum was incubated in the presence of 200 μg/mL 
of Protein A to block antibody Fc fragment reactivity. The cells 
were then washed and labeled with CD3-ECD (Beckman Coulter 
A07748), CD16-PE (Beckman Coulter A07766), and CD56-PC7 
(Beckman Coulter A21692) for 15  min at room temperature. 
Data acquisition and analysis were performed using a Beckman 
Coulter Navios cytometer. The NK lymphocyte subset within the 
PBMCs was gated through CD3/CD56-labeling (CD3−CD56+ 
population). The CD16 and Lamp1/CD107a expression patterns 
within the CD3−CD56+ NK subset were analyzed. ADCC was 
further analyzed by calculating the rituximab–CD107a/Lamp1 
upregulation index (CD107a/Lamp1URI), which is expressed 
as the ratio between the percentage of CD107a/Lamp1 NK cell 
activation toward B cells in the presence (ADCC) or absence of 
rituximab (natural cytotoxicity). The level of CD16 engagement 
was quantified as the ratio between the MFIs of NK CD16 expres-
sion observed after effector PBMCs were incubated with B cell 
targets exposed to 20% human CTL DSA− serum in the presence 
or absence of rituximab and was further defined as the CD16 
downregulation index (CD16DRI).
When PBMCs or splenic cells were used as the target cells, the 
cell preparations were depleted of NK cells prior to being used as 
targets in the NK-CHAT. NK cell depletion was achieved through 
CD16 and CD56 magnetic bead selection (Miltenyi 130-045-701 
and 130-050-401). Briefly, pelleted cells were resuspended in 
60 μL of PBS containing 2 mM EDTA, 0.5% human AB serum 
(SAB), and 20 μL of each set of beads and then incubated on ice 
for 30 min. After a wash step, the fixed NK cells were depleted 
using adapted columns and magnets as recommended by the 
manufacturer (Miltenyi 130-042-201).
Transplant histological assessment
Forty transplant biopsies were retrospectively reassessed and 
scored using the updated conventional Banff diagnosis criteria 
(51) by one experimental renal pathologist (LD) blinded to 
the clinical information. C4d staining of paraffin section was 
performed through immunochemistry (51, 52). The biopsies 
were graded (from 0 to 3) according to the following histo-
logical parameters: glomerulitis (g), tubulitis (t), interstitial 
inflammation (i), intimal arteritis (v), peritubular capillaritis 
(ptc), chronic glomerulopathy (cg), interstitial fibrosis and 
tubular atrophy (ci and ct), and arterial fibrous intimal thick-
ening (cv). The humoral parameters were integrated into a 
humoral histological score by adding the following variables: 
(g + ptc + v + cg + C4d) (36).
statistical analysis
The statistical analyses were performed using Graph Pad Prism 5 
software (GraphPad Software, La Jolla, CA, USA) and IBM SPSS 
Statistics for Windows, Version 20.0 (IBM Corp., Armonk, NY, 
USA). Categorical variables are reported as counts or percent-
ages. The associations between continuous variables were ana-
lyzed using Spearman’s rank correlation analysis. The Chi-square 
test (or Fisher’s exact test when appropriate) was used for the 
comparisons of categorical variables. Group comparisons were 
performed through one-way analysis of variance (ANOVA). 
A Mann–Whitney t test was performed for the comparison of 
non-parametric data from two groups. A p value <0.05 was 
considered to represent a statistically significant difference. In all 
figures, one asterisk (*) denotes p < 0.05, two asterisks (**) denote 
p < 0.01, and three asterisks denote p < 0.001. Clinical, histologi-
cal, functional, and immunological factors associated with the 
degradation of kidney graft function were assessed in a separate 
univariate analysis. The variables identified as significantly asso-
ciated with outcome variables (p < 0.05), that were marginally 
significant (p < 0.20, t) in the univariate analysis, or that are con-
sidered clinically relevant were selected for inclusion in the Cox 
regression model, which analyzed parameters associated with a 
loss in kidney graft function equal to at least 10% of the eGFR 
over the follow-up period of the 148 patients (median duration 
of follow-up: 13.3 months, 25–75th percentile: 12.1–15.1 months 
post-evaluation).
resUlTs
analysis of antibody-Dependent nK cell 
responses in Kidney Transplant 
recipients
The NK-CHAT assay was designed to evaluate the contribution 
of the three components of ADCC responses, i.e., NK effector 
cells, antibodies, and target cells (Figure 1). In the first approach, 
peripheral NK cell cytotoxic activity was evaluated using a 
standardized combination of targets and antibodies, and variable 
sources of circulating effector cells isolated from 148 late KTRs 
were compared to those from 86 healthy controls (Table 1). Flow 
cytometry analysis of CD107a/Lamp1+ NK cell granule exocy-
tosis allowed quantification of natural and antibody-dependent 
cytotoxic activation against a standardized combination of HLA-
negative (K562) target cells or HLA- and CD20-positive B cell 
target cells evaluated in the presence or absence of rituximab. As 
observed for the control cells, the NK cell cytotoxic function was 
highly variable in KTRs (Figure 2A). The variations in the levels 
of NK cell cytotoxic activation toward K562 (p = 0.206) or B cell 
target cells (p = 0.141) were not significantly different between 
the KTR and control groups. Interestingly, although the ADCC 
levels of KTRs with an eGFR < 60 mL/min/1.73 m2 were compa-
rable to those observed in the control group, the NK cell ADCC 
responses were significantly decreased in transplant recipients 
with preserved graft function (eGFR >  60  mL/min/1.73  m2). 
To normalize the interindividual variability of natural NK cell 
cytotoxicity toward B cells, NK-ADCC was further indexed by 
calculating the rituximab–CD107a/Lamp1 upregulation index 
FigUre 1 | Description of the observational and in vitro steps of the study of antibody-dependent nK cell activation using a standardized nK-
cellular humoral activation Test (nK-chaT). Step 1. The standardized ex vivo NK-CHAT evaluation of the variability of KTR NK cell activation toward B cell 
targets coated with anti-CD20 monoclonal antibodies (rituximab). Step 2. In vitro scoring of serum DSA activity toward allogeneic target cells using third-party 
PBMCs isolated from healthy blood donors as immune effector cells.
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(CD107a/Lamp1URI), a ratio of the percentage of CD107a/
Lamp1+ NK cell activation toward B cells in the presence to that 
observed in the absence of rituximab (Figure  2B). Although 
highly variable, the level of rituximab-induced CD107a/Lamp1 
upregulation was maintained across KTRs (median CD107a/
Lamp1URI: 4.1, 25–75th percentile: 2.98–5.79) and was not 
significantly different from that observed in a cohort of healthy 
control individuals (median CD107a/Lamp1URI: 4.5, 25–75th 
percentile: 3.16–6.25, Figure 2B). A multivariate Cox regression 
analysis of the factors associated with CKD progression further 
indicated that this intermediate level of the ADCC responsive-
ness observed in KTRs (CD107a/Lamp1URI > 3) was associated 
with the occurrence of graft function decline (≥10% eGFR loss) 
or graft failure in 34% of the transplanted recipients during the 
mean follow-up period of 13.3 months (Figure 2C and Table 2).
Quantification of Dsa-Dependent cD16 
engagement and nK cell activation 
toward allogeneic cell Targets
Through the introduction of KTR serum as a variable in the 
NK-CHAT assay, we further investigated whether this test 
could assess the variability in DSA-mediated NK cell cytotoxic 
activity, which relies on the structural features of IgGs found 
in complexes in the KTR serum (Figure 1, step 2). Consistent 
with studies that utilized C1q binding as a tool to characterize 
the complement-dependent pathogenicity of DSA, we explored 
whether indexing the Fc–FcR interactions can reflect the 
cytotoxic potential of DSAs found in plasmapheresis samples 
collected during ABMR therapy. Specific binding of the DSAs 
found in plasma to B cells expressing either HLA-A2 or DR4 
antigen was confirmed by flow cytometry cross-match (FCXM, 
Figure  3A). Plasma containing anti-HLA-A2 DSAs induced 
a significant and reproducible modulation of both CD107a/
Lamp1 and CD16 expression on NK cells incubated with distinct 
HLA-A2+ B cell targets (Figure S1A in Supplementary Material). 
A phenotypic analysis of NK cells identified CD16 expression 
as a surrogate marker of NK cell cytotoxic granule exocytosis 
and shows that it has the capacity to reflect the specific humoral 
component of NK cell activation (Figure  3B). A comparative 
NK-CHAT evaluation of DSA+ plasma samples and rituximab 
reactivity was performed using different batches of effector 
PBMCs from distinct healthy donors (n = 25). The NK-CHAT 
scores resulting from the specific recognition of allogeneic B cells 
by DSAs were not significantly different from those observed 
with rituximab (Figure  3B). As observed with rituximab, the 
plasma-driven modulation of CD107a/Lamp1 and CD16 
expression was specific, exhibiting HLA alloantigen recognition 
and effector-dependent variability (Figure 3B). The same results 
were observed using freshly isolated NK cell-depleted human 
AB C
FigUre 2 | analysis of nK cell activation in late kidney transplant recipients. (a) The natural cytotoxicity of NK cells toward HLA-negative K562 cells or 
CD20+ B-lymphocyte target cells was analyzed by multicolor flow cytometry. The expression of CD107a/Lamp1 on the surface of CD3−CD56+ NK cells gated within 
the PBMCs was analyzed. NK cell ADCC toward the same B cell targets was evaluated in the presence of rituximab (Ritux). NK cell activation was evaluated in 148 
KTRs and 86 healthy controls (CTL). The KTR patients were grouped according to graft function as follows: normal graft function (eGFR ≥ 60 mL/min/1.73 m2, 
n = 56) and moderate-to-severe graft dysfunction (eGFR < 60 mL/min/1.73 m2, n = 92). One-way ANOVA was performed to test the significance of NK-ADCC 
using PBMC effector cells obtained from CTLs and the KTR subgroups (Kruskal–Wallis, p = 0.0002). Asterisks indicate the p values as follows: *p ≤ 0.05, 
**p ≤ 0.01, and ***p ≤ 0.001. The box plots show the median values, and the whiskers represent the 5–95 percentiles. (B) Specific analysis of rituximab-induced NK 
cell activation. To analyze the specific contribution of antibodies, NK cell activation toward rituximab-coated B cells was normalized in reference to the baseline 
cytotoxicity of the NK cells toward B cells evaluated in the absence of rituximab by calculating the CD107a/Lamp1 upregulation index (CD107a/Lamp1URI). The 
CD107a/Lamp1URI values observed in the KTR cohort allowed classification of the KTRs as low ADCC responders if their CD107a/Lamp1URI was below 3 (25th 
percentile) or as intermediate or high responders if their CD107a/Lamp1URI value was greater than 3. (c) Kaplan–Meir curves for an eGFR loss of at least 10% or 
graft loss (n = 51) observed during the follow-up period (months post-inclusion in the study) in KTRs with low NK cell activation (CD107a/Lamp1URI ≤ 3) and 
intermediate or high NK cell activation (CD107a/Lamp1URI > 3).
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PBMCs as the allogeneic target cells expressing HLA alloan-
tigens (Figure S1B in Supplementary Material). To normalize 
the variability in the baseline expression of CD16 in KTRs, a 
CD16 downregulation index (CD16DRI) was calculated as the 
ratio of the CD16 MFI measured in response to B cells coated 
with DSA-negative control serum (baseline) to the CD16 MFI 
results from B cells coated with KTR sera. In most cases in which 
the same sources of effector and target B cells were used in the 
NK-CHAT assay, the CD16DRI values measured in response 
to DSA-coated cells were correlated with the CD16DRI values 




FigUre 3 | comparative analysis of rituximab and Dsa-specific nK cell activation. (a) Plasmapheresis samples were obtained during plasma exchange 
therapy from two patients with circulating DSAs and a biopsy-proven ABMR. The binding of anti HLA-A2 (patient 1, Pat1) or anti HLA-DR4 DSA (patient 2, Pat2) to 
B cell targets was revealed by flow cytometry cross-match (FCMX) using a secondary antibody (gray shaded area). FCXM was analyzed in reference to binding and 
was observed when B cells were coated with the control plasma, showing no humoral reactivity (white area). MFI, median fluorescence intensity. (B) Comparative 
analysis of rituximab and DSA-induced NK cell activation toward target cells expressing HLA alloantigens. Flow cytometric analysis of antibody-mediated CD107a/
Lamp1 (upper panel) and CD16 (MFI) (lower panel) expression was performed using NK cells prepared from distinct third-party healthy donors after incubation with 
HLA-A2 homozygous and DR4 heterozygous B cell targets and HLA-A2 DSA+ plasma (n = 17) or HLA-DR4 DSA+ plasma (n = 11). CTL, control plasma with no 
detectable anti HLA antibodies. (c) NK-CHAT analysis of DSA+ plasma. CD16DRI was evaluated using effector cells exposed to B cell targets in the presence of 
rituximab, DSA+ plasma, or DSA− CTL plasma. The specificity of antibody-driven CD16 engagement was analyzed by the addition of Protein A (53), by prior platelet 
absorption (Abs) of the anti-HLA antibodies in plasma, or through the use of IgG purified from ABMR plasma (pIgG DSA+) or control plasmas with no detectable HLA 
antibodies (pIgG CTL). (D) CD16DRI was used to evaluate the reactivity of serum samples obtained during the follow-up period of KTRs toward four different 
allogeneic splenic cells from the day of transplant (D0) to months (M) 90, 91, and 140 after transplant. The target splenic cells were selected according to the 
presence or absence of HLA antigens recognized by anti HLA-A1 or HLA-DR11 DSAs: (o) no relevant HLA antigen, (---) HLA-A1 heterozygote, and ( ) HLA-DR11 
homozygous ( ) or HLA-DR11 heterozygous antigens. An enhanced CD16DRI of NK cells that were exposed to splenic cells expressing DSA cognate HLA 
alloantigen was obtained using serum obtained at M90 from this KTR patient at the time of acute cellular rejection diagnosis. Persistent elevated CD16DRI levels 
were obtained using serum obtained at the times of two consecutive episodes of C4d− diagnosis of chronic ABMR, which occurred at M91 and M140 after 
transplant. The values of CD16 MFI obtained when effector PBMCs exposed to serum in the absence of splenic cells served as controls for baseline activity ( ).
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Antibody-mediated CD16 engagement was partially inhibited 
by Fc blockage using Protein A and by prior removal of DSAs 
from the serum. Specific CD16 engagement via the Fc fragment 
of DSAs was also observed after the exposure of target B cells to 
IgG purified from DSA+ plasma samples (Figure 3C).
The analysis of the use of NK cell-depleted splenic cells, a 
common source of donor cells used in cross-match assays, as cell 
targets in the NK-CHAT showed that CD16 engagement also 
reflected the anti-HLA-A2 DSA-specific recognition of donor 
cells (Figure S2 in Supplementary Material). We used different 
batches of splenic cells to monitor the NK-CHAT reactivity of the 
pre- and posttransplant serum samples obtained from a patient 
who developed HLA-A1 and DR11 dnDSAs associated with graft 
dysfunction and consecutive ABMR episodes (Figure 3D). The 
CD16DRI values evaluated against HLA-DR11 homozygous 
spleen cells were higher than those against DR11 heterozygous 
spleen target cells. Interestingly, in this patient, the increased 
CD16DRI value was associated with the progression of histologi-
cal lesions consistent with C4d–negative ABMR.
nK-chaT evaluation of serum sampled at 
Time of Biopsy-Proven aBMr Diagnosis
To investigate the potential link between CD16DRI and DSA-
mediated allograft injury, the NK-CHAT was performed using 
46 sera samples obtained from 40 KTRs who had undergone 
concomitant transplant biopsies for clinical evaluation (Table 3). 
Among these KTRs, 18 patients were not sensitized, whereas 
the sera collected from 22 patients showed detectable levels of 
dnDSAs (HLA specificities listed in Table 4). The serum-driven 
modulation of the CD16 and CD107a/Lamp1 levels was associ-
ated with the detection of circulating DSAs and the histological 
diagnosis of ABMR (Figure  4A). The CD16DRI values were 
positively correlated with CD107/Lamp1URI (Figure  4B) and 
varied among DSA+ sera (Figure 4C). Although anti-DQ7 DSAs 
with similar MFI values sometimes exhibited variable levels of 
CD16DRI (Table 4, illustration in Figure S3 in Supplementary 
Material), the median CD16DRI values were found to correlate 
with the MFI intensity of DSAs detected by Luminex assays 
(Spearman r =  0.46, p =  0.016). For patients with DSAs and 
ABMR, histological scores (g +  ptc +  v +  cg +  C4d) above 3 
were associated with a higher CD16DRI value (Figure 4C). In 
particular, the NK-CHAT was sufficiently sensitive to index the 
reactivity of an anti-Cw04 DSA in a patient with an ABMR-
related microangiopathy (Table 4, patient 19). Monitoring of the 
pre- and posttransplant sera from 18 of these de novo sensitized 
patients revealed that NK activation was only detected posttrans-
plant, specifically at the time of dnDSA detection (Figure 4C), 
thus allowing evaluation of the CD16DRI values in reference to 
the pretransplant sera.
To illustrate the ability of the NK-CHAT to monitor the 
evolution of DSA reactivity and the potential relevance of NK 
cell activation during humoral rejection, we evaluated a patient 
experiencing her first acute ABMR attack at month 44 with sub-
sequent graft loss. The NK-CHAT analysis revealed a significant 
increase in the CD16DRI value associated with biopsy-proven 
ABMR (Figure  5A). Moreover, the CD16DRI value decreased 
after ABMR treatment (plasmapheresis and rituximab) but was 
markedly increased at the time of graft failure. A transplant 
nephrectomy was performed at month 76 due to graft intoler-
ance syndrome (Figure 5B). A comparative phenotypic analysis 
of circulating and kidney-infiltrating NK cells showed that the 
NK cells constituted 24% of the intra-graft lymphocytes, whereas 
only 2.7% of the peripheral blood lymphocytes at the time of 
transplant nephrectomy were NK cells. When analyzed in refer-
ence to circulating NK cells, a sixfold decrease in the CD16 MFI 
was also observed in the intra-graft NK cells, suggesting that the 
dnDSA-mediated engagement of the CD16 receptor detected by 
the NK-CHAT may reflect the level of humoral in situ NK cell 
activation within the transplant site (Figure 5C).
DiscUssiOn
Our study highlights the potential value of NK cell evaluation in 
monitoring the deleterious effects of alloantibodies in solid organ 
transplantation. Our observational study shows that the intensity 
of NK cell activation, evaluated through a standardized assay in 
response to a monoclonal therapeutic IgG, such as rituximab, 
may be associated with the progression of late graft dysfunction 
in KTRs. In addition, our results demonstrate the potential of the 
NK-CHAT to individualize the intrinsic capacity of an individual 
KTR to mount deleterious humoral immune cytotoxic responses 
against the graft, independently of other factors that are expected 
to impact NK cell and transplant function (step 1, Figure  1). 
The patients with the poorest transplant prognoses 1 year after 
analysis were predominantly those that exhibit at least a threefold 
increase in ADCC reactivity in response to rituximab. Our obser-
vations indicate that, independently of the detection of circulat-
ing DSAs, the individualized NK-CHAT scoring of peripheral 
NK cell activity may provide relevant information concerning 
complement-independent mechanisms that favor the develop-
ment of chronic allograft injury. Because the evaluation of KTRs 
was only previously performed at one time point years after trans-
plant, we cannot exclude the possibility that subclinical levels of 
DSAs, which may have developed prior to evaluation, had already 
promoted chronic NK cell activation in vivo, thus restraining the 
capacity of NK cells from sensitized patients to further respond 
to rituximab. A recent study demonstrated that pre-ligation of 
CD16 by anti-CD20 antibodies could impair antibody-mediated 
NK cell cytotoxicity against tumors (54), thus highlighting the 
exquisite plasticity of CD16_mediated NK cell responses. If 
translated into a simplified test, we expect that such individual-
ized appraisal of the NK-ADCC activation potential may warrant 
closer humoral monitoring and recommend biopsy for a subset 
of immunized patients with high ADCC responsiveness, whereas 
less stringent monitoring of DSAs may be considered in patients 
with lower ADCC reactivity. This variability in KTRs regarding 
NK cell responses also suggests that the NK-CHAT may also be 
of value for anticipating or monitoring the efficiency of rituximab 
treatment in sensitized patients (55, 56).
Consistent with mechanistic evidence showing that NK cells 
play a critical role in mediating long-term transplant kidney injury 
(29), such intrinsic variability in the NK-ADCC responsiveness 
is also expected to condition the level of DSA toxicity in  vivo 
TaBle 3 | characteristics and histological Banff scores of the 40 patients subjected to evaluation of the serum cD16Dri obtained at the time of 
histological diagnosis.
Parameters Patients with Dsa directed against  
B cell targets  
(n = 22)
Patients without Dsa  
(n = 18)
p value
Recipient age at biopsy (years) 52.1 (15) 51.4 (15.4) ns
Male 13 (59%) 13 (72%) ns
Preemptive graft 1 (4%) 1 (6%) ns
risk factors for hla sensitization
Second transplantation 2 (9%) 0 ns
Blood transfusion before graft 9 (41%) 7 (39%) ns
HLA A+ mismatch 2.3 (1) 2.5 (0.9) ns
HLA DR mismatch 1.0 (0.6) 1.0 (0.7) ns
Deceased donors 19 (86%) 18 (100%) ns
Donor age (years) 37.2 (17) 46.1 (17.1) 0.11
Expanded criteria donors 4 (18%) 5 (28%) ns
Delayed graft function 2 (9%) 3 (17%) ns
Time since transplantation (Mo) 124 (72) 62 (69) 0.008
indication for biopsy
Deterioration of graft function 20 (91%) 14 (78%) ns
Investigate proteinuria 2 (9%) 1 (5%) ns
BK virus viremia 0 3 (17%) 0.08
Maintenance immunosuppressive regimen at biopsy
Tacrolimus 10 (45%) 9 (50%) ns
Cyclosporine 12 (54%) 9 (50%) ns
MMF 10 (45%) 8 (44%) ns
Azathioprine 3 (14%) 7 (39%) 0.06
Steroid 17 (77%) 18 (100%) 0.03
graft function at biopsy
Serum creatinine (μmol/L) 230 (80) 200 (66) 0.13
eGFR (mL/min/1.73 m2) 28 (10) 35 (15) 0.15
Proteinuria (g/L) 1.0 (0.20–2) 0.45 (0.10–0.80) 0.04
Panel-reactive antibody at biopsy
Class I 9% (19) 0% 0.004
Class II 16% (14) 0% <0.0001
histological findings
Sclerotic glomeruli (%) 33%(23) 26%(24) ns
g score (0–3) 0.9 0 0.0004
ptc score (0–3) 1.8 0.1 <0.0001
Microcirculation inflammation (g + ptc) 2.7 0.1 <0.0001
g + ptc > 0 19 2 <0.0001
V score (0–3) 0.2 0 ns
cg score (0–3) 1.1 0 0.0004
IF/TA (0–3) 1.7 1.5 ns
cv score (0–3) 1.6 1.1 0.01
Humoral histologic score (g + ptc + v + cg + C4d) 6 (4–8) 0 <0.0001
T-cell-mediated rejection 7 (32%) 3 (17%) ns
Antibody-mediated rejection 20 (91%) 0 <0.0001
nK cell activation
CD107a/Lamp1 URI median (25–75p) 2.1 (1.9–3.9) 1.1 (0.99–1.3) <0.0001
CD16 DRI median (25–75p) 5 (3–17) 0.96 (0.8–1.16) <0.0001
The sera samples were classified into two groups according to the presence or absence of DSAs directed against B cell targets. g, glomerulitis; ptc, peritubular capillaritis, IF/TA, 
interstitial fibrosis/tubular atrophy. The variables are shown as the means (SD), medians (25–75th percentile), or n (%). χ2 tests were used for comparisons of the proportions, and 
unpaired t tests or Mann–Whitney tests were used for the comparisons of continuous variables.
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(24–30). Consistently, we observed that NK cells infiltrating the 
graft of a KTR with ABMR exhibited enhanced in  situ CD16 
engagement compared with peripheral NK cells.
In the second part of our study, we obtained in vitro evidence 
that the NK-CHAT may also act as a powerful tool to discriminate 
the differential ability of DSAs to stimulate CD16-dependent 
NK cell activation (step 2, Figure 1). One unique feature of the 
NK-CHAT is its potential to combine the analysis of two parame-
ters that control the strength of the target/effector cell interactions 
via DSAs through the following mechanisms: (i) Fab recognition 
TaBle 4 | Pra and MFi of 25 Dsa+ serum samples subjected to evaluation of the cD16Dri score at the time of biopsy.






specific MFi toward hla 
alloantigens target  
B-cell 2
a2 a2 B44 B56 cw1 Dr1 Dr4 Dr53 DQ5 DQ7 Median  
cD16Dri  
(n = 2–6)
Pat. 01 – S01 14 33 A3 A29 B56 
DR11 DQ7 
23,000 0 0 0 0 0 0 0 0 0 23,000 17.7
Pat. 02 – S02 15 20 B44 DQ5 9,500 0 0 0 0 0 0 0 3,500 6,000 0 2.0
Pat. 03 – S03 13 DQ5 15,000 0 0 0 0 0 0 0 0 15,000 0 3.5
Pat. 04 – S04 6 DR12 DQ7 12,000 0 0 0 0 0 0 0 0 0 12,000 4.2
Pat. 05 – S05 35 Dr53 12,000 0 0 0 0 0 0 0 12,000 0 0 5.8
Pat. 06 – S06 21 DQ7 13,000 0 0 0 0 0 0 0 0 0 13,000 33.8
Pat. 07 – S07 9 DQ7 2,000 0 0 0 0 0 0 0 0 0 2,000 1.7
Pat. 08 – S08 21 DQ7 15,000 0 0 0 0 0 0 0 0 0 15,000 6.0
Pat. 09 – S09 Bio 1 18 DQ7 9,000 0 0 0 0 0 0 0 0 0 9,000 24.7
Pat. 09 – S09 Bio 2 22 DQ7 15,000 0 0 0 0 0 0 0 0 0 15,000 37.1
Pat. 10 – S10 Bio 1 37 a2, B44 20,000 8,000 8,000 4,000 0 0 0 0 0 0 0 3.6
Pat. 10 – S10 Bio 2 34 a2, B44 5,000 1,500 1,500 2,000 0 0 0 0 0 0 0 1.7
Pat. 10 – S10 Bio 3 90 a2, B44 a a a a 0 0 0 0 0 0 0 5.2
Pat. 11 – S11 5 5 A1 Dr53 10,000 0 0 0 0 0 0 0 10,000 0 0 12.7
Pat. 12 – S12 20 DQ5 10,000 0 0 0 0 0 0 0 0 10,000 0 4.2
Pat. 13 – S13 20 20 a2 B44 DQ5 24,000 2,800 2,800 7,500 0 0 0 0 0 14,000 0 5.1
Pat. 14 – S14 20 Dr53 DQ7 19,000 0 0 0 0 0 0 0 9,000 0 10,000 27.6
Pat. 15 – S15 15 10 A2 DQ5 32,000 14,000 14,000 0 0 0 0 0 0 4,000 0 17.4
Pat. 16 – S16 23 DQ7 14,000 0 0 0 0 0 0 0 0 0 14,000 46.9
Pat. 17 – S17 33 5 B56 DR4 12,500 0 0 0 10,000 0 0 2,500 0 0 0 16.2
Pat. 18 – S18 1 Dr1 500 0 0 0 0 0 500 0 0 0 0 2.9
specific MFi toward hla 
alloantigens Target  
B-cell 2
a3 a3 B7 B35 cw4 Dr10 Dr15 Dr51 DQ5 DQ6
Pat. 19 – S19 15 cw4 9,500 0 0 0 0 9,500 0 0 0 0 0 4.8
Pat. 20 – S20 15 3 a3 A26 C7 
DQ6
16,000 5,000 5,000 0 0 0 0 0 0 0 6,000 9.6
Pat. 21 – S21 60 DQ6 15,000 0 0 0 0 0 0 0 0 0 15,000 1.5
Pat. 22 – S22 19 DR17 DQ6 3,000 0 0 0 0 0 0 0 0 0 3,000 2.3
Pat. 01 – S01 14 33 A3 A29 B56 
DR11 DQ7 
10,000 5,000 5,000 0 0 0 0 0 0 0 0 4.2
Pat. 02 – S02 15 20 B44 DQ5 10,000 0 0 4,000 0 0 0 0 0 6,000 0 1.5
Pat. 03 – S03 13 DQ5 15,000 0 0 0 0 0 0 0 0 15,000 0 4.9
A total of 25 DSA+ sera samples obtained from 22 KTR patients (Pat.) at the time of histological diagnosis were evaluated by CD16DRI scoring. Two distinct B cell targets (HLA genotype-indicated) were used to detect HLA alloantigen 
recognition. Sera obtained from patients 1–3 exhibited DSA+ reactivity toward both target B cells, and tests were evaluated on the two cell targets. The CD16DRI scores were evaluated through at least two independent experiments 
(n = 2–6), and the presented CD16DRI values are the medians of these tests.
HLA specificities and specific MFI of circulating donor specific antibodies (DSA)  towards target alloantigens expressed on B cell lines 1 and 2  are indicated in bold characters.
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FigUre 4 | The nK-chaT evaluation of Dsa reactivity toward B cell targets in sera collected at the time of transplant biopsy. (a) The modulation of 
CD16 (MFI) and CD107a/Lamp1 on NK effector cells exposed to serum-coated B cell targets was analyzed. Forty-three sera samples were collected from 40 KTRs 
at the time of biopsy and grouped according to the detection (DSA+, n = 25 sera obtained in 22 patients) or absence (DSA−, n = 18 patients) of B cell-specific 
circulating DSAs (the DSA specificities and MFI are detailed in Table 4) or to ABMR diagnosis. Rituximab was added to DSA− serum and used as a positive control 
for the test. (B) Correlation of CD16DRI and CD107a/Lamp1URI scores for sera samples collected at the time of biopsy. (c) At the time of transplant biopsy (Bio), 
higher CD16DRI scores were associated with the presence of circulating DSAs (left panel) and humoral histological scores greater than 3 (g + ptc + v + cg + C4d of 
Banff’s classification, right panel). The CD16RI scores of DSA− serum from the same sensitized KTR, obtained prior to the detection of dnDSAs (before Bio), were 
also evaluated in reference to DSA+ serum sampled at the time of biopsy.
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of ex vivo conformational antigens and (ii) Fc structural changes. 
Because a strong CD16DRI was shown to reflect the humoral 
component of NK cell cytotoxic activation in response to DSA, 
we expect that the NK-CHAT evaluation could be limited to the 
measurement of serum-induced CD16 expression.
The scoring of DSA-mediated NK cell activation was 
not restricted to B cell targets expressing high levels of HLA 
antigens but was also performed toward peripheral PBMCs 
and spleen cell targets that express lower physiological levels 
of HLA antigens. The NK-CHAT also detected functional 
immune activation resulting from less commonly evaluated 
alloantibodies, such as the anti-HLA-Cw and DQ7 antibodies. 
Our observations suggest that the sensitivity of the NK-CHAT 
to evaluate the ability of DSAs to bind to alloantigens could be 
comparable or even superior to that of current methods used to 
characterize DSAs.
A major feature of the NK-CHAT is its potential to detect 
Fc-dependent variations in alloantibodies and index their poten-
tial to trigger CD16-mediated NK cell activation in an individual 
KTR. Interestingly, DSAs with a comparable MFI against DQ7 
alloantigens were, in some cases, associated with different ranges 
of CD16DRI values. Thus, our test may also reflect structural 
features of DSAs, which cannot be fully revealed by a SABA. The 
efficiency of FcR-mediated NK cell activation has been reported 
to be dependent on the IgG1/IgG3 subclasses (57) and on the 





























































Longitudinal monitoring of DSA activity




















FigUre 5 | The nK-chaT monitoring of Dsa reactivity and characterization of cD16 engagement of nK cells infiltrating a kidney transplant site. 
(a) Histological assessment of lesions from biopsies of patient 10 at M44 and M76 (transplant nephrectomy). The M44 histological analysis showed peritubular 
capillaritis (cpt = 2, black arrow). At M76, histology revealed arteritis (v = 2, black arrow) and confirmed severe acute inflammatory lesions (t = 3, i = 3, g = 3, 
ptc = 3, v = 2, C4d = 3) with diffuse interstitial edema and chronic vascular lesions (cv = 2) as well as tubular atrophy (ct = 2). The left and right panels show the 
hematoxylin–eosin–saffron (HES) and C4d immunochemical staining of paraffin sections, respectively. (B) The NK-CHAT activity of five sera samples obtained during 
the longitudinal monitoring of patient 10 was analyzed in reference to serum obtained before transplantation (no sensitization). A significant increase in CD16DRI was 
concomitant with the detection of HLA-A2 and anti-B44 dnDSA at M44 as well as histological lesions of ABMR. The CD16DRI level decreased after rituximab 
treatment. The detection of low levels of circulating DSAs at M75 (before graft nephrectomy) was associated with a lowered CD16DRI and no evidence of humoral 
activity within the biopsy. An increased CD16DRI was observed at the time of graft nephrectomy and persisted for 6 months. At these two time points (M76 and 
6 months after graft nephrectomy), the circulating DSA were at saturating titers, which did not allow accurate MFI quantification. (c) Comparative flow cytometric 
analysis of CD16 expression in blood CD3−CD56+ NK cells and infiltrating NK cells isolated from the transplant after nephrectomy.
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antibodies (58). Altered fucosylation patterns in the Fc tails 
of DSAs have been shown to alter Fc binding to FcγRIIIA and 
C1q (59) and may represent a critical regulatory determinant 
of both ADCC- and complement-dependent DSA toxicity (60). 
The CD16 expression levels and polymorphisms have also been 
shown to influence NK cell activation (40, 57). Although the 
KTR CD16 genotype was not included in the initial study design, 
we expect that depending on the FcγRIIIA genetic background 
of the recipient, CD16-mediated NK-CHAT responses may be 
differentially triggered by IgG based on the presence of a valine 
or phenylalanine residue at position 158 of the FcγRIIIA receptor.
Although the NK-CHAT was mostly associated with the results 
of the C4d histological staining of the biopsy, we demonstrated 
that the NK-CD16DRI-based monitoring of DSA activity toward 
splenic cells was associated with the progression of ABMR lesions 
that occurred in the absence or prior to the detection of C4d 
histological staining. A longitudinal follow-up of serum reactivity 
against allogeneic targets revealed that the NK-CHAT scores were 
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lowered after ABMR desensitization therapy and were associated 
with the progression of biopsy-proven graft lesions.
Altogether, the results of our study provide evidence that 
independently of the DSA MFI intensity, the NK-CHAT reactiv-
ity may serve as a hallmark of clinically relevant features that 
discriminate the ability of DSAs to target allograft injury.
Our work has several limitations. First, we only analyzed the 
degradation of eGFR in 148 KTRs, and the ability of the NK-CHAT 
to predict kidney dysfunction needs to be demonstrated through 
CD16 monitoring in a larger cohort of KTRs and over a longer 
follow-up period. We also need to challenge our test with more 
stringent end-points, such as graft failure and patient mortality. 
Considering the major role of complement in the pathogenesis 
of ABMR, the absence of DSA C1q and C3d-binding tests and 
the use of complement-depleted serum constitute additional 
limitations. Moreover, the NK-CHAT scores were obtained using 
sera that were collected at the time of the clinically indicated 
transplant biopsy, and the value of the test requires control testing 
of sera that develop dnDSAs in the absence of allograft rejection 
or exhibit signs of vascular lesions in the absence of detectable 
levels of DSAs. Due to a low number of cases, the establishment 
of a firm link between the intensity of NK cell activation and the 
severity of ABMR lesions or clinical outcome was not possible 
at this stage. Therefore, it may be relevant to investigate whether 
the NK-CHAT only serves as a powerful detector of DSAs or if it 
could predict subclinical ABMR in a cohort of KTRs developing 
dnDSAs as well as anticipate the evolution and severity of ABMR 
histological lesions.
Despite these limitations, we provide novel evidence of the role 
of NK cells in renal allograft dysfunction and tools to monitor the 
interindividual variability of humoral alloimmune responses in 
immunized patients. A full use of the NK-CHAT using a combina-
tion of recipient NK cells and serum combined with donor target 
cells should improve the ability to identify immunized patients 
who are at higher risk of subsequent graft dysfunction. Our study 
highlights the importance of designing and translating novel 
assays that combine the simultaneous evaluation of the recipient 
IgG and FcR to individualize the evaluation of the humoral risk of 
a given recipient. In particular, we developed a simple phenotypic 
assay that integrates both environmental and genetic parameters 
that condition antibody–antigen interactions combined with FcR 
engagement (43, 45). Because this non-invasive assay of CD16 
engagement was shown to be reproducible, inexpensive, and 
easy to implement for routine monitoring, prospective studies 
are warranted to assess the clinical relevance of the NK-CHAT 
using recipient NK cells and serum reactivity against target cells 
of donor origin.
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